WHAT IS CLAIMED IS:

1. A compound of the formula:



wherein R_1, R_2, R_3, R_4, R_5 and R_6 are each chemical residues.

2. The compound of Claim 1, wherein R_1 and R_2 are hydrogen.

3. The compound of Claim 1, wherein R_1 and R_2 are alkyl groups selected from the group consisting of straight chains, branched and cyclic alkyl groups.

4. The compound of Claim 3, wherein R_1 and R_2 each contain one to thirteen carbons.

5. The compound of Claim 4, wherein the R_1 and R_2 groups are substituted with amine groups selected from the group consisting of primary, secondary, tertiary and quaternary amines.

6. The compound of Claim 5, wherein the amine group substitution is on a terminal carbon.

7. The compound of Claim 1, wherein R_5 is a halogen selected from the group consisting of fluorine, chlorine and bromine.

8. The compound of Claim 1, wherein R_6 is an alkyl alcohol group selected from the group consisting of methyl alcohol, ethyl alcohol, isopropyl alcohol and n-propyl alcohol.

9. The compound of Claim 1, wherein R_6 is a N-alkylcarboxamido group selected from the group consisting of N-methylcarboxamido, N-ethylcarboxamido, N-isopropylcarboxamido, and N-n-propylcarboxamido.

10. A compound of the formula:



wherein R_1, R_2, are each: 

R_3, R_4, and R_5 are each hydrogen;

and R_6 is: 

11. A pharmaceutical composition for treating hypertension in a mammal comprising:

an effective amount of the compound according to Claim 1 and a pharmaceutically acceptable carrier to the mammal in need thereof.

12. A pharmaceutical composition for treating acute ischemia in a mammal comprising:

an effective amount of the compound according to Claim 1 and a pharmaceutically acceptable carrier to the mammal in need thereof.

13. The pharmaceutical composition of Claim 12 wherein treating includes prophylactic effects.

14. A pharmaceutical composition for producing controlled vasodilation in a mammal comprising:

an effective amount of the compound according to Claim 1 and a pharmaceutically acceptable carrier to the mammal in need thereof.

15. A pharmaceutical composition for use as a sympathetic blocking agent comprising:

an effective amount of the compound according to Claim 1 and a pharmaceutically acceptable carrier to the mammal in need thereof.

16. A pharmaceutical composition containing an adenosine analogue that lowers blood pressure while not causing clinically relevant changes in heart rate.

17. A method for treating hypertension in a mammal comprising:

administering an effective amount of the compound of Claim 1 and a pharmaceutical carrier to the mammal in need thereof.

18. A method for controlling vasodilation in a mammal comprising:

administering an effective amount of the compound of Claim 1 and a pharmaceutical carrier to the mammal in need thereof.

19. The method of Claim 18, wherein the risk of cardiovascular events is reduced.

20. A method for identifying areas of cardiac infarct in a patient comprising:

administering an effective amount of the compound of Claim 1 such that the area of cardiac infarct is detectable upon imaging.